Chest CT in the Emergency Department for Diagnosis of COVID-19 Pneumonia: Dutch Experience

S. Schalekamp MD PhD\(^1\), C.P. Bleeker-Rovers, MD PhD\(^2\), L.F.M. Beenen MD PhD\(^3\), H.M.E. Quarles van Ufford MD PhD\(^4\), H.A. Gietema MD PhD\(^5\)\(^-\)\(^20\), J.L. Stöger MD PhD\(^6\), V. Harris MD PhD\(^7\)\(^-\)\(^8\), M.H.E. Reijers MD PhD\(^9\), J. Rahamat-Langendoo MD PhD\(^10\), D.A. Korevaar MD PhD\(^11\), L.P. Smits MD PhD\(^12\), C. Korteweg MD\(^13\), T. van Rees Vellinga MD\(^1\), M. Vermaat\(^1\) MD, P.M. Stassen MD PhD\(^15\), H. Schep MD\(^16\), R. Wijnakker MD\(^17\), F.J. Borm\(^18\) MD, A.S.M. Dofferhoff MD PhD\(^19\), W.M. Prokop MD PhD\(^1\).

1. Radboud University Medical Center, Department of Radiology, Nuclear Medicine and Anatomy, Nijmegen, the Netherlands.
2. Radboud University Medical Center, Department of Internal Medicine, Division of Infectious Diseases, and Radboud Center for Infectious Diseases, Nijmegen, the Netherlands.
3. Amsterdam UMC, Location AMC, Department of Radiology, Amsterdam, the Netherlands.
4. Medical Center Haaglanden, Department of Radiology, the Hague, the Netherlands.
5. Maastricht University Medical Center+, Department of Radiology and Nuclear Medicine, Maastricht, the Netherlands.
6. Leiden University Medical Centre, Department of Radiology, Leiden, the Netherlands.
7. Amsterdam Institute for Global Health and Development, Department of Global Health, Amsterdam, the Netherlands.
8. Amsterdam UMC, Location AMC, Department of Infectious Diseases, Internal Medicine, Amsterdam, the Netherlands.
9. Radboud University Medical Center, Department of Pulmonology, Nijmegen, the Netherlands.
10. Radboud University Medical Center, Department of Medical Microbiology, and Radboud Center for Infectious Diseases, Nijmegen, the Netherlands.
11. Amsterdam UMC, Location AMC, Department of Respiratory Medicine, Amsterdam, the Netherlands.
12. Amsterdam UMC, Location AMC, Department of Internal Medicine, Amsterdam, the Netherlands.
13. Medical Center Haaglanden, Department of Pulmonology, the Hague, the Netherlands.
14. Canisius-Wilhelmina Ziekenhuis, Department of Radiology, Nijmegen, the Netherlands.
15. Maastricht University Medical Center+, Department of Internal Medicine, Maastricht, the Netherlands.
16. Leiden University Medical Centre, Department of Internal Medicine, Leiden, the Netherlands.
17. Leiden University Medical Centre, Department of Infectious Diseases, Leiden, the Netherlands.
18. Leiden University Medical Centre, Department of Pulmonology, Leiden, the Netherlands.
19. Canisius-Wilhelmina Ziekenhuis, Department of Internal Medicine, Nijmegen, the Netherlands.
20. GROW School for Oncology and Developmental Biology

**Corresponding author:**

Steven Schalekamp

Geert Grooteplein zuid 10

6525GA Nijmegen, the Netherlands

[Steven.schalekamp@gmail.com](mailto:Steven.schalekamp@gmail.com)

**Keywords:** COVID-19, Computed Tomography, Diagnosis, Multicenter, Multidisciplinary.

**Manuscript type:** Original research
Key Results

1. Radiologist interpretation of emergency department chest CT exams from 1070 patients in six medical centers yielded an area under the receiver operating characteristics curve (AUC) of 0.87 for a diagnosis of coronavirus disease 2019 (COVID-19) with real-time reverse-transcription polymerase chain reaction as reference standard.

2. A positive chest CT interpretation showed high performance for the diagnosis of COVID-19 pneumonia with odds-ratios of 25.9.

3. For symptom duration less than 48 hours, the AUC of chest CT for the diagnosis of COVID-19 fell to 0.71 (P<.001).

Summary Statement: Chest CT analysis using the COVID-19 reporting and data system (CO-RADS) is fast and achieves a high performance for diagnosing COVID-19, particularly when symptom duration is greater than 48 hours.

Abbreviations:

AUC: area under the ROC curve
COVID-19: coronavirus disease 2019
CO-RADS: COVID-19 reporting and data system
ROC: receiver-operating characteristics
RT-PCR: real-time reverse transcription-polymerase chain reaction

See also the editorial by Elicker.
Abstract

Background:

Clinicians need rapid and reliable diagnosis of coronavirus disease 2019 (COVID-19) for proper risk stratification, isolation strategies, and treatment decisions.

Purpose:

To assess the real-life performance of radiologist emergency department chest CT interpretation for diagnosing COVID-19 during the acute phase of the pandemic, using the COVID-19 reporting and data system (CO-RADS).

Materials and Methods:

This retrospective multicenter study included consecutive patients who presented to emergency departments in six medical centers between March and April 2020 with moderate to severe upper respiratory symptoms suspicious for COVID-19. As part of clinical practice, chest CT was obtained for primary workup and scored using the 5-point CO-RADS scheme for suspicion of COVID-19. CT was compared with SARS-CoV-2 RT-PCR, and a clinical reference standard established by a multidisciplinary group of clinicians based on RT-PCR, COVID-19 contact history, oxygen therapy, timing of RT-PCR testing and likely alternative diagnosis. Performance of CT was estimated using area under the receiver operating characteristics curve (AUC) analysis and diagnostic odds ratios (OR) against both reference standards. Subgroup analysis was performed based on symptom duration grouped presentations of < 48 hours, 48 hours through 7 days, and > 7 days.
Results:

A total of 1070 patients (median age 66, IQR 54-75, 626 men) were included, of whom 536/1070 (50%) had a positive RT-PCR, 137/1070 (13%) patients were considered to have a possible or probable COVID-19 based on the clinical reference standard. Chest CT yielded an AUC of 0.87 (95%CI 0.84-0.89) compared with RT-PCR and 0.87 (95%CI 0.85-0.89) compared with the clinical reference standard. A CO-RADS score ≥4 yielded an OR of 25.9 (95%CI 18.7-35.9) for a COVID-19 diagnosis by RT-PCR, and an OR of 30.6 (95%CI 21.1-44.4) by the clinical reference standard. For symptom duration of less than 48 hours, the AUC fell to 0.71 (95%CI 0.62-0.80; P<.001).

Conclusion:

Chest CT analysis using the COVID-19 reporting and data system (CO-RADS) enables rapid and reliable diagnosis of COVID-19, particularly when symptom duration is greater than 48 hours.
Introduction

The ongoing coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought about a need for timely and high diagnostic performance tests for detecting COVID-19. The reference standard for diagnosing COVID-19 is a SARS-CoV-2 real-time reverse-transcription polymerase chain reaction (RT-PCR) in respiratory tract specimens. Unfortunately, RT-PCR has limited sensitivity, and clinical test performance is dependent on test sample quality, viral load kinetics, and duration of symptoms (1-5). Moreover, the time required for laboratory testing and reporting of RT-PCR results can be substantial, which is undesirable in crowded emergency departments. Hence, in hospitals there is a need for rapid and reliable diagnostics of COVID-19 for appropriate isolation in patient groups with high suspicion of disease. CT is widely available and offers the potential of fast triage and robust rapid diagnosis with limited burden to patients. However, the use of CT scanning for diagnosing COVID-19 has been strongly debated with mixed recommendations (6, 7).

The Dutch Radiological Society has developed a standardized reporting scheme for chest CT in patients presenting with moderate to severe symptoms of COVID-19(8). This ‘COVID-19 reporting and data system’ (CO-RADS) is a likelihood classification for the presence of pulmonary involvement of COVID-19, with scores varying from 1 (very low suspicion) to 5 (very high suspicion), dependent on the type and distribution of the pulmonary abnormalities (Table 1). This CT classification has moderate to substantial interobserver agreement(8). Yet, the performance of CO-RADS and its clinical applicability have not been validated in a real-life setting.

This multicenter study aimed to assess the performance of the CO-RADS classification for diagnosing COVID-19 in patients presenting to the emergency department with moderate to severe symptoms suspicious for COVID-19, both for the overall study group and stratified by duration of symptoms. Chest CT was compared with two reference standards: SARS-CoV-2 RT-PCR, as well as a clinical diagnostic reference standard.
Materials and Methods

Ethics

This study was approved by the institutional review boards of all participating centers. Informed consent was waived by the local IRBs prior to the study.

Patients

This retrospective, multicenter study in 4 university medical centers and 2 large teaching hospitals evaluated consecutive adult patients presenting to the emergency department between March 20th and April 3rd 2020* (April 10th for center F) with moderate to severe symptoms suspicious of COVID-19 who received a non-contrast enhanced CT-scan at presentation. Suspected COVID-19 was defined as (a) cough and clinically relevant dyspnea requiring hospital admission with or without fever >38 °C, (b) fever without a known cause or (c) fever with anosmia. As standard practice in all these hospitals, patients received a chest CT scan if there was a potential indication for hospital admission.

Patients were excluded from analysis if RT-PCR was not performed or if they were transferred from other hospitals with a known, RT-PCR proven COVID-19 diagnosis. Patients who only had a chest CT with intravenous contrast were also excluded. Patients without reported CO-RADS were excluded from further analysis. Demographic and clinical information, including duration of symptoms, was retrieved from electronic patient records.

Imaging and CO-RADS reporting

Non-contrast enhanced CT scans were obtained with various CT scanners (Canon Aquilion Vision, Canon Aquilion One Genesis, Canon Medical Systems, Otawara Japan; Somatom Force, Somatom Definition Flash, Somatom Definition AS+, Siemens Healthineers, Erlangen, Germany; Lightspeed 16, GE Healthcare, Chicago, IL; Ingenuity 128, Philips Healthcare, Amsterdam, the Netherlands) according to existing local imaging protocols, preferably a low dose protocol (Table E1). All scans were prospectively evaluated by local radiologists with varying levels of experience as part of regular care,
without knowledge of RT-PCR results. The current study exclusively used the CO-RADS classification as adjudicated in the official radiological report.

Reference Standard

CT was compared with two reference standards. The first reference standard was SARS-CoV-2 RT-PCR of a clinical specimen. COVID-19 infection was considered ‘proven’ if at least one RT-PCR for SARS-CoV-2 in a throat, nasal, sputum, bronchoalveolar lavage fluid and/or fecal sample was positive. If initial RT-PCR was negative, subsequent RT-PCR testing was generally performed, depending on the clinical likelihood of disease.

A reference standard for COVID-19 diagnosis has yet to be established. While widely used, a large proportion of patients with negative RT-PCR remain clinically highly suspect for COVID-19. In daily routine, this subgroup is isolated and remains in isolation until COVID-19 is ruled out clinically and/or by repeated RT-PCR in order to avoid nosocomial COVID-19 transmission to non-infected patients. To address the limited sensitivity of PCR and the need to avoid missing a diagnosis in patients who have COVID-19 in the inpatient setting, the study established a clinical reference standard that was designed to be highly sensitive (Figure 1).

In this clinical reference standard, RT-PCR positive patients were designated as ‘proven’ COVID-19. RT-PCR negative patients were classified into either ‘probable’ COVID-19, ‘possible’ COVID-19 or ‘no’ COVID-19 based on clinical data. These patients were classified by local teams of clinical physician assessors blinded to CT-scan and laboratory results. First, assessors determined if an alternative diagnosis explained the presenting symptoms, in which case the patient was classified as ‘no’ COVID-19. If no alternative diagnosis was established, patients were classified as a ‘probable’ diagnosis of COVID-19 if they had contact with persons with suspected or proven COVID-19, required high oxygen therapy (5L O₂ for ≥24 hours or 3L O₂ for ≥48 hours), required ICU admission due to respiratory failure, or in case of unexplained death during admission. The remaining patients were classified as ‘possible’ COVID-19 if their nasopharyngeal RT-PCR had been collected less than 2 or greater 7 days after onset.
of symptoms. Classification in the ‘proven’, ‘probable’ and ‘possible’ COVID-19 categories were considered positive for the clinical reference standard.

Statistical Analysis

Data from all participating centers were collected in line with GDPR standards. Statistical analyses were performed using SPSS statistics version 25 (IBM, Armonk, New York). Continuous data are presented as mean ± standard deviation or median and interquartile range (IQR). Categorical data are presented as proportions. Performance estimates are reported as proportions along with confidence intervals. Receiver operating characteristic (ROC) analysis was performed calculating the area under the curve (AUC) for CO-RADS against both reference standards. Sensitivity, specificity, and diagnostic odds ratios at various cut-off points of the CO-RADS classification were calculated. Results are displayed per center and for all centers combined. Since pulmonary involvement may not be immediately visible, and because RT-PCR loses sensitivity at a later stage after beginning of symptoms, subgroup analysis was performed based on the duration of symptoms, grouping presentations of less than 48 hours, 48 hours through 7 days, and more than 7 days. Significance testing between subgroups of ROC analysis was performed with MedCalc Statistical Software version 19.3.1 (MedCalc Software Ltd, Ostend, Belgium; https://www.medcalc.org; 2020). P values <.05 were considered significant.
Results

Patient demographics

Of 1833 total patients with suspected COVID-19, 763 were excluded from the study group. Eighty-eight patients were excluded because they were not diagnosed in an emergency department, 403 were excluded because they had no or only mild symptoms, 129 had no RT-PCR test, 53 other had already a RT-PCR proven COVID-19, 56 had no CO-RADS in the original report, and 34 had a contrast enhanced CT, leaving a total of 1070 patients were included in this study (Figure 2). In the study group 626/1070 (59%) were men. Median age was 66 (IQR 54-75). Median duration of symptoms at admission was 7 days (IQR 3-10). Baseline patient characteristics for each center are shown in Table 2.

536/1070 (50%) patients had ‘proven’ COVID-19 based on a positive RT-PCR; in 497/536 (93%) of these, the initial RT-PCR was positive. According to the clinical reference standard, there were an additional 70/1070 (7%) RT-PCR negative patients with ‘probable’ COVID-19, 67/1070 (6%) with ‘possible’ COVID-19 and 397/1070 (37%) patient with ‘no’ COVID-19. Of the 1070 CT scans, 235/1070 (22%) were scored as CO-RADS 1, 140/1070 (13%) as CO-RADS 2, 134/1070 (13%) as CO-RADS 3, 120/1070 (11%) as CO-RADS 4 and 441/1070 (41%) as CO-RADS 5 (Table 3).

Validation results CO-RADS

Using RT-PCR as a reference standard, AUC was 0.87 (95%CI 0.84-0.89; range across hospitals 0.82-0.90; Table 4). At a CO-RADS positivity threshold of ≥4, sensitivity was 86% (95%CI 83%-89%), and specificity was 81% (95%CI 78%-84%), and the odds ratio for a COVID-19 diagnosis was 25.9 (95%CI 18.7-35.9).

Compared with the clinical reference standard, AUC was 0.87 (95%CI 0.85-0.89; range across hospitals 0.85-0.89). At a CO-RADS positivity threshold of ≥4, sensitivity was 77% (95%CI 74%-81%) and specificity was 90% (95%CI 87%-93%), and the odds ratio for a COVID-19 diagnosis was 30.6 (95%CI
Results per CO-RADS category are visualized in Figure 3, and results at different CO-RADS cut-offs are displayed in Table 5.

**Duration of symptoms**

Pulmonary manifestations of COVID-19 on CT (CO-RADS ≥3) were seen in 67% of the patients with a symptom duration of less than 48 hours and in 95% of the patients with a symptom duration of more than 48 hours. The performance of CT was worse in the subgroup of patients with symptom duration of less than 48 hours (n=220/1070) compared with patients with a symptom duration greater than 48 hours for the diagnosis of COVID-19 with an AUC of 0.71 (95%CI 0.62-0.80; p<.001) against RT-PCR, and 0.68 (95%CI 0.60-0.76; p<.001) against the clinical reference standard. In the subgroups of patients with symptom duration between 48 hours and 7 days (n=430/1070) AUC was 0.86 (95%CI 0.83-0.90) against RT-PCR, and 0.89 (95%CI 0.86-0.93) against the clinical reference standard. For patients with a symptom duration of more than 7 days (n=376/1070) AUC was 0.86 (95%CI 0.82-0.90) against RT-PCR, and 0.89 (95%CI 0.85-0.93) against the clinical reference standard (Figure 4).
Discussion

Large numbers of patients suspected of coronavirus disease 2019 (COVID-19) have flooded the emergency departments during the first peak of COVID-19, creating the need for rapid and reliable diagnosis to guide clinicians in risk stratification, isolation strategies and treatment decisions. During this pandemic we demonstrated high performance of chest CT using the COVID-19 reporting and data system (CO-RADS) for the diagnosis of COVID-19 in clinical practice. This high level of performance suggests that chest CT can be used to optimize/expedite emergency care for patients suspected of having COVID-19 pneumonia.

The AUC of CO-RADS for the diagnosis of COVID-19 was 0.87 (95% CI 0.84-0.89) when compared with RT-PCR and reached a sensitivity of 86% at a specificity of 81% at a CO-RADS positivity threshold of ≥ 4.

When compared to our clinical reference standard, we also found good performance of CT, reaching an AUC of 0.87 (95% CI 0.85-0.89), and sensitivity of 77% at a specificity of 90% and an OR of >30. Our subgroup analysis based on duration of symptoms showed lower performance of chest CT when performed within the first 48 hours of symptoms with an AUC of 0.71 (95% CI 0.62 – 0.80) against RT-PCR and 0.68 (95% CI 0.60-0.76) against the clinical reference standard (p<.001).

Previous studies have reported higher sensitivities for CT diagnosis of COVID-19(3, 9, 10), but this may be exaggerated due to biased samples and cohorts(11). Reports on CT specificity are scarce and thus far disappointingy indicating values often below 50%(3, 6, 12-17). Previous studies did not use a well circumscribed imaging classification system (3, 10). Our study may indicate that employing CO-RADS improves CT performance in diagnosis of COVID-19 in clinical practice. Our observation that CT had lower performance within the first 48 hours of symptoms, is in line with a recent observational study(18). Since sensitivity of RT-PCR declines after 7 days of symptoms(1, 19), CT may aid diagnosing COVID-19 in patients presenting with a longer duration of symptoms.
Beyond diagnostic challenges, the first wave of COVID-19 also introduced patient management issues related to workflow, isolation, personal protective equipment, and treatment decisions. During initial risk estimation in the emergency department, RT-PCR results are usually not immediately available and even when they come available, negative RT-PCR does not exclude COVID-19, especially when the pre-test probability of COVID-19 is high (20). Our study showed that CT can be a useful risk stratification tool for COVID-19: which may be advantageous in to counteract emergency department crowding(21).

However, 41/375 (11%) of CO-RADS 1 and 2 patients had RT-PCR proven COVID-19. Retrospective analysis of corresponding CT scans did not reveal misclassification errors in the original reporting. An explanation may be that these patients had no pulmonary manifestations of COVID-19. The proportion of patients with only extrapulmonary symptoms is not well documented but may be in the order of 3-26%(22-24). The lack of pulmonary findings on CT for this subset of RT-PCR positive patients underscores that CO-RADS 1-2 alone should not be used to rule-out COVID-19. Lack of pulmonary involvement on CT, however, may allow for earlier de-isolation when initial RT-PCR is negative.

41/120 (34%) of CO-RADS 4 and 60/441 (14%) of CO-RADS 5 patients did not have a positive RT-PCR. But a substantial number of these RT-PCR negative patients, 21/41 (51%) for CO-RADS 4 category and 40/60 (67%) for CO-RADS 5 category, were considered as a probable or possible COVID-19 according to our clinical reference standard, and therefore would not qualify for removal from isolation. An alternative diagnosis, like an alternative pulmonary infection or congestive heart failure was established in 21/40 (53%) of the ‘no’ COVID-19 patients with a CO-RADS of 4 and 5 (Figure 5 and Figure 6; Table E2). We recommend patients with CO-RADS 4 or 5 and a negative RT-PCR should remain isolated in a single bedroom until repeat RT-PCR is negative or an alternative diagnosis is found that explains the complaints.

In patients with an uncertain CT diagnosis (i.e. CO-RADS 3), 35/134 (26%) had a positive RT-PCR and 76/134 (57%) were classified as ‘no’ COVID-19 in the clinical reference standard. The added value of CT in this group was limited. Fortunately, only 134/1070 (13%) of all patients had a CO-RADS 3
classification. This proportion of uncertain diagnosis is still relatively high compared with other reporting and data systems such as BI-RADS (1.2-14%)(25) and LUNG-RADS (6%)(26), but much lower than PI-RADS (40%)(27).

Our study has limitations. The CO-RADS classification was introduced in the early phase of the first COVID-19 peak in the Netherlands. Radiologists may not have been optimally trained, which could have negatively influenced performance. In addition, we focused on patients presenting to the emergency department and incidence of COVID-19 was high. Our findings may not be reproducible to lower-incidence settings. Our clinical reference standard was designed to be highly sensitive but was not validated in a control group and may be false positive, especially in the ‘possible’ COVID-19 category. Furthermore, before implementation of this CT strategy, good infection control processes need to be in place. Specifically, cleaning the CT scanner room and safe room turnover for the safe scanning of new patients must be considered.

The implications of our results are of potential importance. Chest CT exams interpreted using the CO-RADS system allow for a rapid test result in the emergency department of patient with suspected COVID-19 pneumonia. This suggests a potential role for chest CT in helping to optimize risk stratification and isolation strategies of patients urgently presenting for hospital care during the first and second wave of this pandemic.

In conclusion, using the CO-RADS chest CT reporting system for emergency department subjects, pulmonary manifestations of COVID-19 were detected in more than 95% of patients with moderate to severe upper respiratory symptoms 48 hours after symptom onset. CO-RADS score greater than or equal to 4 provided odds ratios above 25 for the diagnosis of COVID-19.
References

1. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med 2020;382(12):1177-1179.

2. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;25(3):10.2807/1560-7917.ES.2020.25.3.2000045.

3. Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology 2020:200642.

4. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA 2020;323(18):1843-1844.

5. Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. J Med Virol 2020.

6. Simpson S, Kay FU, Abbara S, et al. Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. J Thorac Imaging 2020.

7. Rubin GD, Ryerson CJ, Haramati LB, et al. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. Radiology 2020:201365.

8. Prokop M, van Everdingen W, van Rees Vellinga T, et al. CO-RADS - A categorical CT assessment scheme for patients with suspected COVID-19: definition and evaluation. Radiology 2020:201473.

9. Fang Y, Zhang H, Xie J, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology 2020:200432.

10. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382(18):1708-1720.

11. Waller JV, Kaur P, Tucker A, et al. Diagnostic Tools for Coronavirus Disease (COVID-19): Comparing CT and RT-PCR Viral Nucleic Acid Testing. AJR Am J Roentgenol 2020:1-5.

12. Kim H, Hong H, Yoon SH. Diagnostic Performance of CT and Reverse Transcriptase-Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis. Radiology 2020:201343.

13. Hope MD, Raptis CA, Shah A, Hammer MM, Henry TS, six signatories. A role for CT in COVID-19? What data really tell us so far. Lancet 2020;395(10231):1189-1190.

14. Cheng Z, Lu Y, Cao Q, et al. Clinical Features and Chest CT Manifestations of Coronavirus Disease 2019 (COVID-19) in a Single-Center Study in Shanghai, China. AJR Am J Roentgenol 2020;215(1):121-126.

15. Zhu W, Xie K, Lu H, Xu L, Zhou S, Fang S. Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei, China. J Med Virol 2020.
16. Himoto Y, Sakata A, Kirita M, et al. Diagnostic performance of chest CT to differentiate COVID-19 pneumonia in non-high-epidemic area in Japan. Jpn J Radiol 2020;38(5):400-406.

17. Caruso D, Zerunian M, Polici M, et al. Chest CT Features of COVID-19 in Rome, Italy. Radiology 2020:201237.

18. Bernheim A, Mei X, Huang M, et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology 2020:200463.

19. Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert Rev Mol Diagn 2020;20(5):453-454.

20. Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. N Engl J Med 2020

21. Berger FH, Korner M, Bernstein MP, et al. Emergency imaging after a mass casualty incident: role of the radiology department during training for and activation of a disaster management plan. Br J Radiol 2016;89(1061):20150984.

22. Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol 2020;115(5):766-773.

23. Han C, Duan C, Zhang S, et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. Am J Gastroenterol 2020

24. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020;69(6):1002-1009.

25. Baum JK, Hanna LG, Acharyya S, et al. Use of BI-RADS 3-probably benign category in the American College of Radiology Imaging Network Digital Mammographic Imaging Screening Trial. Radiology 2011;260(1):61-67.

26. Pinsky PF, Gierada DS, Black W, et al. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment. Ann Intern Med 2015;162(7):485-491.

27. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017;389(10071):815-822.
### Table 1: Chest CT CO-RADS Classification for the Diagnosis of COVID-19

| Classification | Level of suspicion for pulmonary involvement of COVID-19 | Summary |
|----------------|----------------------------------------------------------|---------|
| CO-RADS 0      | non-interpretable                                        | Scan technically insufficient |
| CO-RADS 1      | very low                                                 | Normal or non-infectious       |
| CO-RADS 2      | low                                                      | Typical for other infection but not COVID-19 |
| CO-RADS 3      | equivocal                                                | Features compatible with COVID-19, but also other diseases |
| CO-RADS 4      | high                                                     | Suspicious for COVID-19        |
| CO-RADS 5      | very high                                                | Typical for COVID-19           |
| CO-RADS 6      | proven                                                   | RT-PCR positive for SARS-CoV-2 |

**Typical CT features:** ground-glass opacities, with or without consolidations, in lung regions close to visceral pleural surfaces, including the fissures (subpleural sparing is allowed) AND multifocal bilateral distribution. And one of the following confirmatory patterns: ground-glass regions; crazy paving; patterns compatible with organizing pneumonia; thickened vessels within parenchymal abnormalities.

**Suspicious CT features:** as typical findings, but not located in contact with the visceral pleura, or strictly unilaterally located, predominant peribronchovascular distribution, or superimposed on severe diffuse pre-existing pulmonary abnormalities.

Adapted from Prokop et al. (8)

Abbreviations: COVID-19 = coronavirus disease 2019; RT-PCR = real-time reverse-transcription polymerase chain reaction; CO-RADS = COVID-19 reporting and data system; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
Table 2: Baseline Patient Characteristics per Center

| Characteristics                      | Center | Total |
|--------------------------------------|--------|-------|
|                                     | A.     | B.    | C.     | D.     | E.     | F.     |       |
| Patients                            | 172    | 262   | 173    | 175    | 194    | 94     | 1070   |
| M:F                                 | 112:60 | 142:120 | 102:71 | 95:85  | 122:72 | 53:41  | 626:444 |
| Median age in years (IQR)           | 66 (51-74) | 67 (55-76) | 59 (47-70) | 68 (54-76) | 71 (59-79) | 68 (56-76) | 66 (54-75) |
| Duration of symptoms                |        |       |        |        |        |       |       |
| Median days of complaints (IQR)     | 6 (2-9) | 7 (4-10) | 7 (3-10) | 6 (2-10) | 6,5 (3-9) | 7 (3-10) | 7 (3-10) |
| < 48 hours (n)                      | 49     | 32    | 34     | 42     | 41     | 22     | 220    |
| > 48 hours – 7 days (n)             | 65     | 115   | 64     | 69     | 81     | 36     | 430    |
| More than 7 days (n)                | 55     | 104   | 64     | 55     | 64     | 34     | 376    |
| Unknown (n)                         | 3      | 11    | 11     | 9      | 8      | 2      | 44     |
| Reference standard                  |        |       |        |        |        |       |       |
| No COVID-19                         | 54 (31%) | 66 (25%) | 56 (32%) | 99 (57%) | 79 (41%) | 43 (46%) | 397 (37%) |
| Possible COVID-19                   | 16 (9%)  | 17 (7%)  | 21 (12%) | 8 (5%)  | 1 (1%)  | 4 (4%)  | 67 (6%) |
| Probable COVID-19                   | 22 (13%) | 24 (9%)  | 11 (6%)  | 6 (3%)  | 4 (2%)  | 3 (3%)  | 70 (7%) |
| Proven COVID-19                     | 80 (47%) | 155 (59%) | 85 (49%) | 62 (35%) | 110 (57%) | 44 (47%) | 536 (50%) |

Abbreviations: COVID-19 = coronavirus disease 2019; IQR = interquartile range.
### Table 3: CO-RADS CT Score per Reference Standard Category

| Reference standard                  | CO-RADS 1 | CO-RADS 2 | CO-RADS 3 | CO-RADS 4 | CO-RADS 5 | total |
|-------------------------------------|-----------|-----------|-----------|-----------|-----------|-------|
| No COVID-19                         | 179       | 102       | 76        | 20        | 20        | 397   |
| Possible COVID-19                   | 21        | 11        | 14        | 8         | 13        | 67    |
| Probable COVID-19                   | 10        | 11        | 9         | 13        | 27        | 70    |
| RT-PCR proven COVID-19              | 25        | 16        | 35        | 79        | 381       | 536   |
| **Total**                           | **235**   | **140**   | **134**   | **120**   | **441**   | **1070** |

Abbreviations: COVID-19 = coronavirus disease 2019; CO-RADS = COVID-19 reporting and data system; RT-PCR = real-time reverse-transcription polymerase chain reaction.
Table 4: Performance of CO-RADS

| Center | RT-PCR proven COVID-19 | Clinical reference standard for COVID-19 |
|--------|------------------------|----------------------------------------|
|        | AUC (95% CI)            | AUC (95% CI)                          |
| A.     | 0.86 (0.81-0.92)        | 0.87 (0.82-0.93)                      |
| B.     | 0.82 (0.77-0.88)        | 0.88 (0.83-0.93)                      |
| C.     | 0.89 (0.84-0.94)        | 0.86 (0.81-0.92)                      |
| D.     | 0.87 (0.81-0.93)        | 0.85 (0.78-0.91)                      |
| E.     | 0.87 (0.81-0.92)        | 0.86 (0.80-0.91)                      |
| F.     | 0.90 (0.83-0.97)        | 0.89 (0.82-0.96)                      |
| All    | 0.87 (0.84-0.89)        | 0.87 (0.85-0.89)                      |

Area under the receiver operating characteristics curve of the COVID-19 reporting and data system (CO-RADS) for each center per reference standard. Abbreviations: AUC = area under the curve; COVID-19 = coronavirus disease 2019. RT-PCR = real-time reverse-transcription polymerase chain reaction.
| CO-RADS cut-off | RT-PCR proven COVID-19 | | | Clinical reference standard for COVID-19 | | |
|---|---|---|---|---|---|---|
| | Sensitivity (95% CI) | Specificity (95% CI) | Odds ratio (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | Odds ratio (95% CI) |
| 3 and higher | 92% (90% - 94%) | 63% (58% - 67%) | 20.2 (14.0 - 29.0) | 86% (83% - 89%) | 71% (66% - 75%) | 14.9 (11.0 - 20.3) |
| 4 and higher | 86% (83% - 89%) | 81% (78% - 84%) | 25.9 (18.7 - 35.9) | 77% (74% - 81%) | 90% (87% - 93%) | 30.6 (21.1 - 44.4) |
| 5 and higher | 71% (67% - 75%) | 89% (86% - 91%) | 19.4 (14.0 - 26.9) | 62% (59% - 66%) | 95% (93% - 97%) | 31.5 (19.6 - 50.7) |

COVID-19 = coronavirus disease 2019; CO-RADS = COVID-19 reporting and data system. RT-PCR = real-time reverse-transcription polymerase chain reaction.
Figure 1: Flowchart clinical reference standard. Abbreviations: COVID-19 = coronavirus disease 2019; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; PCR = polymerase chain reaction; ICU = intensive unit; BAL = bronchoalveolar lavage.
Figure 2: Inclusion flowchart. Patient were excluded when they were not diagnosed in the emergency department, had no or only mild symptoms, did not have a RT-PCR, and if patient was RT-PCR proven at time of CT scan or no CO-RADS reporting system was used in the original report. * 10th of April for center F. Abbreviations: COVID-19 = coronavirus disease 2019; RT-PCR = real-time reverse-transcription polymerase chain reaction; CO-RADS = COVID-19 reporting and data system.
Figure 3: Performance per CO-RADS category. Bar chart of percentage ‘proven’ COVID-19, ‘probable’, ‘possible’, and ‘no’ COVID-19 per CO-RADS CT score. Abbreviations: COVID-19 = coronavirus disease 2019; CO-RADS = COVID-19 reporting and data system.
Figure 4: ROC analysis based on durations of symptoms. (a) ROC analysis based on durations of symptoms for CO-RADS against RT-PCR. (b) ROC analysis based on durations of symptoms for CO-RADS against clinical reference standard. Blue line: <48 hours complaints (n=52/220 RT-PCR positive); red line: 48 hours – 7 days complaints (n=239/430 RT-PCR positive); grey line: >7 days complaints (n=232/376 RT-PCR positive). Abbreviations: ROC = receiver operating characteristics; RT-PCR = real-time reverse-transcription polymerase chain reaction; AUC = area under the curve.
Figure 5: Example chest CT scans of patients with a true positive (case 1) and false positive (case 2) CO-RADS 4 score. (case 1). True positive CO-RADS 4 chest CT: (a,b) two axial slices and (c) a coronal slice of a 79-year-old female with 9 days of symptoms. CT shows diffuse ground-glass opacities close to visceral pleural surfaces but superimposed on emphysematous changes. Also note the widened esophagus. Coronavirus disease 2019 was RT-PCR confirmed. (case 2) False positive CO-RADS 4 chest CT: (d,e) two axial slices and (f) a coronal slice of a 51-year-old female with 2 days of symptoms. CT shows bilateral multifocal areas of consolidation with halo and subtle areas of ground glass without contact to visceral pleural surfaces. RT-PCR for SARS-CoV2 was repeatedly negative and an alternative diagnosis was established with a blood culture confirmed line sepsis.
Figure 6: Example chest CT scans of patients with a true positive (case 3) and false positive (case 4) CO-RADS 5 score. (case 3) True positive CO-RADS 5 chest CT: two axial slices (a,b) and a coronal slice (c) of a 69-year-old male with 7 days of symptoms. CT shows bilateral multifocal areas of groundglass and consolidation in vicinity of the visceral pleural surface. Also, few thickened vessels in areas of groundglass are observed. Coronavirus disease 2019 was RT-PCR confirmed. (case 4) False positive CO-RADS 5 chest CT: two axial slices (d,e) and a coronal slice (f) of a 42-year-old male with more than 7 days of symptoms. CT shows diffuse groundglass opacities in the close vicinity of visceral pleural surfaces. Also, a crazy paving pattern is observed. RT-PCR for SARS-CoV2 was negative, and a diagnosis of pneumocystis jirovecii pneumonia was made based on bronchoalveolar lavage fluid.
### Table E1: CT Scanner Details and Reconstruction Slice Thickness of COVID-19 Chest CT Scans per Participating Hospital

| Hospital | Scanner brand | Type               | kV | Estimated mean DLP (in mGy*cm) | Reconstruction slice thickness (in mm) |
|----------|---------------|--------------------|----|--------------------------------|--------------------------------------|
| A        | Canon         | Aquilion Vision    | 120| 50                             | 0.5                                  |
| B        | Philips       | Ingenuity 128      | 100| 120                            | 1.0                                  |
| C        | Siemens       | Somatom Force      | 120| 40                             | 1.0                                  |
| D        | Siemens       | Somatom Definition AS+ | 120| 140                            | 0.5                                  |
| E        | GE Healthcare | Lightspeed 16      | 120| 380                            | 1.25                                 |
| F        | Canon         | Aquillion Genesis One | 120| 250                            | 1.0                                  |

kV= kilovoltage; DLP = dose length product.
| Alternative diagnosis                     | Number of patients |
|------------------------------------------|--------------------|
| Congestive heart failure                 | 4                  |
| Influenza A                              | 2                  |
| Human metapneumovirus                    | 3                  |
| Pneumocystis jirovecii pneumonia         | 1                  |
| Other pneumonia                          | 3                  |
| Auto-immune lung disease                 | 1                  |
| Asthma/hypersensitivity                  | 3                  |
| Intoxication                             | 1                  |
| Non-pulmonary infection                  | 2                  |
| Pulmonary embolism                       | 1                  |
| **Total**                                | **21**             |

This table shows the number of specific alternative diagnosis (21/40 (53%) that were established in the ‘no’ COVID-19 patients with a chest CT score CO-RADS of 4 and 5.